Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-468 | Ceritinib | ALK | RTK | 0.76749 | -0.7415 | 0.4050 | 0.1730 | 1.6622 | 1.3833 | 0.99574 |
HCC1428 | Doxorubicin | Chemo | Chemotherapy | 0.0047408 | -0.7396 | 0.8955 | 0.2242 | 0.5182 | 0.029971 | 0.95944 |
BT-20 | Ceritinib | ALK | RTK | 1.5315 | -0.7365 | 0.2591 | 0.1255 | 1.7439 | 2.7905 | 0.99717 |
HCC1500 | ABT-737 | Bcl2/XL | Misc | 0.0085142 | -0.7359 | 1.1288 | 0.3716 | 0.9283 | 0.022222 | 0.99554 |
HCC70 | Buparlisib | pan PI3K | PI3K/mTOR | 0.43342 | -0.7274 | 0.4614 | 0.1434 | 1.1927 | 1.0047 | 0.99537 |
MDA-MB-361 | Doxorubicin | Chemo | Chemotherapy | 0.012289 | -0.7224 | 0.9125 | 0.1900 | 2.1676 | 0.017167 | 0.96442 |
MDA-MB-134-VI | Taxol | Chemo | Chemotherapy | 0.00012515 | -0.7183 | 1.3004 | 0.3511 | 0.5352 | 0.00075273 | 0.89205 |
HCC1500 | Doxorubicin | Chemo | Chemotherapy | 0.016258 | -0.7134 | 0.7518 | 0.1833 | 0.7212 | 0.058468 | 0.98572 |
PDX1328 | Dinaciclib | pan CDK | Cell cycle | 0.011496 | -0.7107 | 0.7519 | 0.2292 | 3.5560 | 0.014708 | 0.9982 |
MDA-MB-468 | Cediranib | VEGFR/cKIT | RTK | 3.9154 | -0.7083 | 0.1649 | 0.0970 | 3.0423 | 5.6183 | 0.9962 |
PDXHCI002 | Topotecan | Topo I | Chemotherapy | 0.0066461 | -0.7006 | 1.0199 | 0.1157 | 0.8130 | 0.015555 | 0.94766 |
HCC70 | AZD7762 | CHK1/2 | Cell cycle | 0.040563 | -0.7002 | 0.8995 | 0.3250 | 2.5054 | 0.056277 | 0.99456 |
CAMA-1 | Ceritinib | ALK | RTK | 1.797 | -0.6988 | 0.2366 | 0.0972 | 1.5849 | 3.5941 | 0.99647 |
BT-20 | Dinaciclib | pan CDK | Cell cycle | 0.018482 | -0.6979 | 0.6791 | 0.3193 | 3.4864 | 0.02362 | 0.99822 |
MDA-MB-436 | Ceritinib | ALK | RTK | 0.49893 | -0.6974 | 0.4169 | 0.1006 | 0.9667 | 1.4927 | 0.99602 |
HCC1395 | AZD7762 | CHK1/2 | Cell cycle | 0.02128 | -0.6899 | 0.8845 | 0.2607 | 2.2723 | 0.028104 | 0.96763 |
MDA-MB-453 | Cediranib | VEGFR/cKIT | RTK | 2.7824 | -0.6894 | 0.1569 | 0.0768 | 3.0858 | 3.7659 | 0.99464 |
MDA-MB-453 | Ceritinib | ALK | RTK | 0.36617 | -0.6866 | 0.4840 | 0.1577 | 1.1705 | 0.84209 | 0.99139 |
HCC70 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.15092 | -0.6846 | 0.5796 | 0.1546 | 0.7043 | 0.64661 | 0.98584 |
PDX1258 | Ceritinib | ALK | RTK | 2.081 | -0.6841 | 0.2165 | 0.0876 | 1.5671 | 4.1949 | 0.9759 |
HCC70 | Cisplatin | Chemo | Chemotherapy | 1.3073 | -0.6832 | 0.2650 | 0.0820 | 1.3165 | 3.0116 | 0.99076 |
MDA-MB-134-VI | Tivantinib | MET | RTK | 0.15045 | -0.6776 | 0.6505 | 0.1737 | 2.2582 | 0.21541 | 0.99657 |
PDXHCI002 | Abemaciclib | CDK4/6 | Cell cycle | 0.047944 | -0.6767 | 0.7662 | 0.1664 | 0.6873 | 0.18848 | 0.98885 |
MDA-MB-361 | AZD7762 | CHK1/2 | Cell cycle | 0.0076402 | -0.6753 | 1.0533 | 0.2116 | 2.0458 | 0.010426 | 0.97675 |
HCC1428 | Dinaciclib | pan CDK | Cell cycle | 0.017078 | -0.6716 | 0.6610 | 0.2408 | 2.9825 | 0.02239 | 0.9979 |